AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-K$ELTP

Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2027 ended June 30, 2026

ELITE PHARMACEUTICALS INC /NV/ (ELTP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2027 ended June 30, 2026 and Provides Conference Call Information Conference Call Scheduled for Friday, August 14, 2026 at 11:30 AM EDT Northvale, NJ – August 13, 2026: Elite P

Original reporting
SEC EDGAR 8-K
Published Aug 13, 2026, 8:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 8:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$ELTP
Neutral
medium confidence
Mentioned
$ELTP
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ELTPNeutralLow
01

Why it matters

The filing itself is a disclosure event and sets expectations for the Aug 14 conference call, but the provided excerpt does not include the actual financial results or any forward-looking guidance.

02

Market read

This is primarily a procedural disclosure update tied to quarterly results; actionable trading depends on the missing Exhibit 99.1 and the 10-Q details.

03

What to watch

Traders should verify Exhibit 99.1 and the attached 10-Q for any revenue, margin, cash balance, debt, or outlook changes that are not present in the scraped text.

Relevance 7/10Novelty 3/10Timing: after-hours filing Aug 13, with conference call scheduled Aug 14 11:30 AM EDT

Background

The SEC 8-K reports Item 2.02 results of operations and financial condition, referencing a quarterly Form 10-Q for the first quarter ended June 30, 2026 and a press release furnished as Exhibit 99.1.

Company-level read

Ticker impact

$ELTPNeutralMedium confidence
Context

Elite Pharmaceuticals filed its quarterly 10-Q results for the first quarter ended June 30, 2026 and scheduled a follow-up conference call Aug 14.

Expected impact

Near-term volatility is possible around the underlying 10-Q/press-release details, but this specific text alone is unlikely to drive a directional move.

Evidence & confidence

The article confirms the existence/timing of the quarterly results and call, yet does not include the actual earnings numbers, outlook, or any discrete event beyond disclosure mechanics.

Market effects

Sector

Limited signal for the broader pharma sector because the excerpt contains no drug, trial, or regulatory catalyst.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

If the omitted exhibit (press release) contains material beats/misses or guidance changes, the trading impact could be higher than this excerpt suggests.

Key entities

  • issuer
    Elite Pharmaceuticals, Inc.

    OTCQB-listed company filing an 8-K for quarterly results and scheduling a conference call.

  • executive
    Nasrat Hakim

    President and CEO signing the 8-K.

Read at source← All news

Related articles

$ELTPLow

Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2026

ELITE PHARMACEUTICALS INC /NV/ (ELTP) filed an SEC Form 8-K — Results of Operations and Financial Condition. false 0001053369 0001053369 2026-06-29 2026-06-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 June 29, 2026

SEC EDGAR 8-K
$OXYHighAI 8/10

Susquehanna reiterates Positive rating on Occidental stock at $77

Susquehanna reiterated a Positive rating on Occidental Petroleum (OXY) with a $77 price target. OXY's Q3 results beat expectations, with adjusted EPS of $1.91 and production of 1,427 Mboe/d. The stock has a P/E ratio of 12.74 and is considered undervalued. Management guided Q4 production and maintained capital expenditure guidance. OXY generated $2.8B in free cash flow and reduced debt by $1.8B. Wells Fargo lowered its price target to $76 but kept an Overweight rating.

investing.com
$EDRYMed

EuroDry Ltd. (EDRY): Financial results for 9M 2026

EuroDry Ltd. (EDRY) furnished an SEC Form 6-K — earnings release. INFORMATION CONTAINED IN THIS FORM 6-K REPORT Attached to this Report on Form 6-K as Exhibit 1 is a copy of the press release issued by EuroDry Ltd. (the “Company”) on November 11, 2026: EuroDry Ltd. Reports Results for the Quarter and Nine-Month Period Ended September 30, 2026.

SEC EDGAR 6-K
$IPWRMed

Ideal Power Reports Third Quarter 2026 Financial Results

Ideal Power Inc. (IPWR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Ideal Power Reports Third Quarter 2026 Financial Results AUSTIN, TX – November 12, 2026 -- Ideal Power Inc. (Nasdaq: IPWR) (“Ideal Power,” the “Company,” “we,” “us” or “our”), developer and provider of its innovative and widely patented B-TRAN® bidirectional semicond

SEC EDGAR 8-K
$DGIIHighAI 8/10

Digi International Reports Fourth Fiscal Quarter and Full Year Fiscal 2026 Results

DIGI INTERNATIONAL INC (DGII) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Digi International Reports Fourth Fiscal Quarter and Full Year Fiscal 2026 Results Record Quarterly Revenue of $143M, Record End of Quarter ARR of $197M Quarterly Cash Flow From Operations of $42M (Minneapolis, MN, November 11, 2026) - Digi International Inc. ("Digi"

SEC EDGAR 8-K